KDM6B and neuroblastoma: The efficacy of GSK-J4 monotherapy in NB has been confirmed by in vitro and in vivo studies in animals, and JMJD3 (histone demethylase Jumonji D3, also called KDM6B) was identified as a key target of GSK-J4 in NB [5, 6].